TXTao Xi

Tao Xi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tao Xi has a total of 469 co-authors. Here are the top co-authors by number of shared publications:

  • Lufeng Zheng

    School of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China

    29 shared publications
  • Yingying Xing

    School of Life Science and Technology, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China; Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China

    29 shared publications
  • Xiaoman Li

    Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China

    16 shared publications
  • Wei Liu

    School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China

    12 shared publications
  • Hai Liu

    School of Life Science and Technology, School of Engineering, Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University Nanjing People's Republic of China

    11 shared publications
  • Haiwei Ni

    School of Life Science and Technology, Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University Nanjing China

    11 shared publications

Latest Publications

  • 1‐Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1

    by Hai Qin, Yi Zhou, Hai Liu, Yaqin Yuan, Qianqian Guo, Manqin Yuan, Tao Xi, Yujie Zhang

    Cytochrome P450 (CYP) 4Z1 (CYP4Z1) has recently garnered much interest as its expression predicts a poor prognosis and as a oncogene in breast cancer, and overexpressed in other many cancers. We previously showed that CYP4Z1 acts as a promoter of cancer stem cells (CSCs) to facilitate the occurrence and development of breast cancer. Here, RNA sequencing found that 1‐benzylimidazole (1‐Benzy) held a preferable correlation with breast cancer and suppressed the expression of CSC makers. Further functional experiments, including mammary spheroid formation, wound‐healing, transwell‐invasion, detection of tumor initiation, and metastatic ability, showed that 1‐Benzy suppressed the stemness and metastasis of breast cancer cells. Additionally, we further demonstrated that CYP4Z1 is necessary for 1‐Benzy‐mediated suppression on breast cancer stemness and 1‐Benzy exerted a weaker effect in breast cancer cells with CYP4Z1 knockdown. Taken together, our data suggest that 1‐Benzy might be a potential drug suppressing breast cancer stemness via targeting CYP4Z1.


  • Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis

    by Yue Yang, Yuanyuan Lu, Chunhua Zhang, Qianqian Guo, Wenzhou Zhang, Ting Wang, Zhuolu Xia, Jing Liu, Xiangyu Cheng, Tao Xi, et al.

    Breast cancer stem cells (BCSCs) are positively correlated with the metastasis, chemoresistance, and recurrence of breast cancer. However, there are still no drugs targeting BCSCs in clinical using for breast cancer treatment. Here, we tried to screen out small-molecule compounds targeting BCSCs from the phenazine library established by us before. We focused on the compounds without affecting cell viability and screened out three potential compounds (CPUL119, CPUL129, CPUL149) that can significantly attenuate the stemness of breast cancer cells, as evident by the decrease of stemness marker expression, CD44+/CD24– subpopulation, mammary spheroid-formation ability, and tumor-initiating capacity. Additionally, these compounds suppressed the metastatic ability of breast cancer cells in vitro and in vivo. Combined with the transcriptome sequencing analysis, ferroptosis was shown on the top of the most upregulated pathways by CPUL119, CPUL129, and CPUL149, respectively. Mechanistically, we found that these three compounds could trigger ferroptosis by accumulating and sequestering iron in lysosomes through interacting with iron, and by regulating the expression of proteins (IRP2, TfR1, ferritin) engaged in iron transport and storage. Furthermore, inhibition of ferroptosis rescued the suppression of these three compounds on breast cancer cell stemness. This study suggests that CPUL119, CPUL129, and CPUL149 can specifically inhibit the stemness of breast cancer cells through triggering ferroptosis and may be the potential compounds for breast cancer treatment.


  • Open Access

    Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis

    by Mengyao Qin, Yu Xin, Yong Bian, Xuan Yang, Tao Xi, Jing Xiong

    Pregnane X receptor (PXR) is a member of the nuclear receptor superfamily that is activated by a variety of endogenous metabolites or xenobiotics. Its downstream target genes are involved in metabolism, inflammation and processes closely related to cancer. However, the stability regulation of PXR protein resulting from post-translational modification is still largely undefined. In the present study, primary mouse hepatocytes, hepatoma HepG2 cells and HEK 293T cells were used to investigate gene expression and protein interactions. The role of kinases was evaluated by RNA interference and overexpression constructs with or without PXR phosphorylation site mutations. The activity of CYP3A4 and P-gp was determined by enzymatic and substrate accumulation assays. It was found that E3 ubiquitin ligase TRIM21 mediates the ubiquitination and degradation of PXR and plays an important role in regulating the activity of PXR. On this basis, PXR phosphorylation-associated kinases were evaluated regarding regulation of the stability of PXR. We found cyclin dependent kinase 2 (CDK2) exclusively phosphorylates PXR at Ser350, promotes its disassociation with Hsp90/DNAJC7, and leads to subsequent TRIM21-mediated PXR ubiquitination and degradation. As well-known CDK inhibitors, dinaciclib and kenpaullone stabilize PXR and result in elevated expression and activity of PXR-targeted DMETs, including carboxylesterases, CYP3A4 and P-gp. The suppressed degradation of PXR by CDK2 inhibitors denotes dinaciclib-induced promotion of PXR-targeted genes. The findings of CDK2-mediated PXR degradation indicate a wide range of potential drug–drug interactions during clinical cancer therapy using CDK inhibitors and imply an alternative direction for the development of novel PXR antagonists.


  • Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis

    by Haiwei Ni, Guojing Ruan, Cheng Sun, Xuan Yang, Zhenyan Miao, Jifei Li, Ying Chen, Hai Qin, Yichen Liu, Lufeng Zheng, et al.

    Tanshinone IIA is the active constituent extracted from Salvia Miltiorrhza. Numerous studies have shown that Tanshinone IIA could inhibit tumor proliferation and metastasis, including gastric cancer. However, the effect of Tanshinone IIA on gastric cancer cell stemness stays unclear. Here, we found that Tanshinone IIA could reduce gastric cancer cell stemness through detecting spheroid‐forming, flow cytometry analysis, and the expression of stemness markers (OCT3/4, ALDH1A1, and CD44). Mechanistically, Tanshinone IIA increased the level of lipid peroxides and decreased glutathione level in gastric cancer cells, both of which are the markers of ferroptosis. Similarly, ferroptosis inducers (erastin, sulfasalazine, and sorafenib) reduced gastric cancer cell stemness. Additionally, the inhibitory effects of Tanshinone IIA on GC cell stemness were reversed by ferroptosis inhibitor (Fer‐1) or overexpression of SLC7A11, which is a critical ferroptosis inhibitor. Therefore, we revealed that Tanshinone IIA inhibited the stemness of gastric cancer cells partly through inducing ferroptosis.


  • Open Access

    MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis

    by Haiwei Ni, Hai Qin, Cheng Sun, Yichen Liu, Guojing Ruan, Qianqian Guo, Tao Xi, Yingying Xing, Lufeng Zheng

    Background: Gastric cancer stem cells (CSCs) are the main causes of metastasis and drug resistance. We previously indicated that miR-375 can inhibit Helicobacter pylori-induced gastric carcinogenesis; here, we aim to explore the effects and mechanisms of miR-375 on gastric cancer (GC) cell stemness. Methods: Lentivirus infection was used to construct GC cells with ectopic expression of miR-375. In vitro and in vivo experiments, including analysis of tumor spheroid formation, CD44+ sub-population with stemness, stemness marker expression, and tumor-initiating ability, were performed to evaluate the effects of miR-375 on the stemness of GC cells. Furthermore, microarray and bioinformatics analysis were performed to search the potential targets of miR-375 in GC cells. Luciferase reporter, RNA immunoprecipitation, and RNA-FISH assays were carried out to verify the targeting of miR-375. Subsequently, combined with tissue microarray analysis, erastin-resistant GC cells, transmission electron microscopy, a series of agonists and oxidative stress markers, the underlying mechanisms contributing to miR-375-mediated effects were explored. Results: MiR-375 reduced the stemness of GC cells in vitro and in vivo. Mechanistically, SLC7A11 was identified as a direct target of miR-375 and miR-375 attenuated the stemness of GC cells mainly through triggering SLC7A11-dependent ferroptosis. Conclusion: MiR-375 can trigger the ferroptosis through targeting SLC7A11, which is essential for miR-375-mediated inhibition on GC cell stemness. These results suggest that the miR-375/SLC7A11 regulatory axis could serve as a potential target to provoke the ferroptosis and thus attenuate the stemness of GC cells.


  • Helicobacter pylori induces gastric cancer via down‐regulating miR‐375 to inhibit dendritic cell maturation

    by Zhenxing Zhang, Simiao Chen, Menghui Fan, Guojing Ruan, Tao Xi, Lufeng Zheng, Le Guo, Feng Ye, Yingying Xing

    Background: Recent studies and clinical samples have demonstrated that Helicobacter pylori could induce the downregulation of miR‐375 in the stomach and promote gastric carcinogenesis. However, whether the immune cells are affected by Helicobacter pylori due to the downregulation of miR‐375 is unclear.Materials and methods: In this study, we constructed an overexpression and knockdown of miR‐375 and Helicobacter pylori infection cell models in vitro. In addition, the maturity of dendritic cells (DCs) and the expression of IL‐6, IL‐10, and VEGF at the transcriptional and translational levels were analyzed. Changes in the JAK2‐STAT3 signaling pathway were detected. In vivo, the number changes in CD4+ T and CD8+ T cells and the size changes of tumors via models of transplantable subcutaneous tumors were also analyzed.Results: A cell model of Helicobacter pylori and gastric cancer was used to identify the expression of miR‐375 and the maturity of dendritic cells. This study found that Helicobacter pylori could downregulate miR‐375, which regulates the expression of cytokines IL‐6, IL‐10, and VEGF in the stomach. MiR‐375 regulated the expression of cytokines IL‐6, IL‐10, and VEGF through the JAK2‐STAT3 signaling pathway in vitro. In addition, we found that Helicobacter pylori regulates the maturation of dendritic cells through miR‐375. These results were further verified in vivo, and miR‐375 diminishes tumor size was also demonstrated. This study showed that immature DCs caused a decrease in the number of CD4+ and CD8+ T cells.Conclusions: This study demonstrated that Helicobacter pylori can inhibit miRNA‐375 expression in the stomach. Downregulated miR‐375 activates the JAK2‐STAT3 pathway. Activating the JAK2‐STAT3 signaling pathway promotes the secretion of IL‐6, IL‐10, and VEGF, leading to immature differentiation of DCs and induction of gastric cancer.


  • HET0016 attenuates the stemness of breast cancer cells through targeting CYP4Z1

    by Hai Liu, Hai Qin, Yi Zhou, Yin Yuan, Yichen Liu, Ying Chen, Yue Yang, Haiwei Ni, Tao Xi, Lufeng Zheng

    Ours and other previous studies have shown that CYP4Z1 is specifically and highly expressed in breast cancer, and acts as a promoter for the stemness of breast cancer cells. Here, we explored whether targeting CYP4Z1 could attenuate the stemness of breast cancer cells using HET0016, which has been confirmed to be an inhibitor of CYP4Z1 by us and others. Using the transcriptome‐sequencing analysis, we found that HET0016 suppressed the expression of cancer stem cell (CSC) markers and stem cell functions. Additionally, HET0016 indeed reduced the stemness of breast cancer cells, as evident by the decrease of stemness marker expression, CD44+/CD24− subpopulation with stemness, mammary‐spheroid formation, and tumor‐initiating ability. Moreover, HET0016 suppressed the metastatic capability through in vitro and in vivo experiments. Furthermore, we confirmed that HET0016 suppressed CYP4Z1 activity, and HET0016‐induced inhibition on the stemness and metastasis of breast cancer cells was rescued by CYP4Z1 overexpression. Thus, our results demonstrate that HET0016 can attenuate the stemness of breast cancer cells through targeting CYP4Z1.


  • MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling

    by Qiong Zhao, Yichen Liu, Ting Wang, Yue Yang, Haiwei Ni, Hai Liu, Qianqian Guo, Tao Xi, Lufeng Zheng


  • Open Access

    Transcriptional Factor Yin Yang 1 Promotes the Stemness of Breast Cancer Cells by Suppressing miR-873-5p Transcriptional Activity

    by Qianqian Guo, Ting Wang, Yue Yang, Lanlan Gao, Qiong Zhao, Wenzhou Zhang, Tao Xi, Lufeng Zheng